Health
Promising Data for Preop Checkpoint Inhibition in NSCLC – MedPage Today
Major response rate of 21%, encouraging survival with single-agent atezolizumab
A fifth of patients with operable early-stage non-small cell lung cancer (NSCLC) had major pathologic responses (MPR) and more than 40% had pathologic downstaging after neoadjuvant atezolizumab (Tecentriq), a prospective multicenter trial showed.
Results showed that 30 of 144 evaluable patients attained MPR, including pathologic complete response (pCR) in 10 patients. Downstaging occurred in 66 of 155 evaluable patients following preoperative treatment with atezolizumab, and 29 patients had upstaging…
-
General20 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News23 hours agoTips to improve engagement – Proctor
-
Noosa News22 hours agoPolice appeal for information over suspected link in torture and murder cases
-
Noosa News17 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says